Neurocrine Biosciences | NBIX - Equity Capital And Reserves


Neurocrine Biosciences reported $3.69B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -5.94B 721M Jun/2026
Acadia Pharmaceuticals USD 1.31B 58.54M Jun/2026
Agios Pharmaceuticals USD 1.03B 83.09M Jun/2026
ALKERMES USD 1.81B 57.02M Jun/2026
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
Biogen USD 18.85B 196.3M Jun/2026
BioMarin Pharmaceutical USD 6.32B 109.58M Jun/2026
Cytokinetics USD -173.49M 653.08M Jun/2026
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Exelixis USD 1.94B 225.57M Mar/2026
Gilead Sciences USD 11.74B 11.77B Jun/2026
Halozyme Therapeutics USD 143.54M 76.09M Jun/2026
Incyte USD 6.34B 721.58M Jun/2026
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
Nektar Therapeutics USD 576.22M 486.38M Mar/2026
Neurocrine Biosciences USD 3.69B 286.2M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Prothena USD 286.89M 25.72M Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Repligen USD 2.11B 6.57M Jun/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sarepta Therapeutics USD 1.53B 22.7M Jun/2026
Teva Pharmaceutical Industries USD 7.75B 475M Jun/2026
Ultragenyx Pharmaceutical USD -291M 55M Jun/2026
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026